Clinical trial NCT06918548: Evaluating the Efficacy of NeoThelium FT in the Treatment of Pressure Injuries
Official title: Evaluation of the Efficacy of NeoThelium FT in the Healing of Chronic Pressure Ulcers: A Randomized Controlled Multicenter Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pressure Injury
Keywords: Chronic wounds
Wound Medicine
Cellular, Acellular, Matrix-like Product (CAMP)
Cellular and/or Tissue Product (CTP)
Dehydrated Complete Human Placental Membrane (dCHPM)
Lead sponsor: NuScience Medical Biologics, LLC
Sponsor class: INDUSTRY
Collaborators: name: SygNola, LLC
First posted: 2025-04-09
Enrollment: 148
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The subject will be randomized to one of the following treatments:

* Standard of care
* NeoThelium FT in addition to standard of care
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating pressure injuries.

Detailed description: This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care alone, or standard of care plus NeoThelium FT. As this is a post-marketing study, it will gather information about how effective the treatment is in treating pressure injuries. All subjects will complete two week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 16 weeks. Secondary endpoints consist of wound area reduction rates, time to closure, follow-up closure, and pain assessment.

Eligibility criteria: Inclusion Criteria:

1. Male or Female, 18 years of age or older
2. Subject has a medical diagnosis of Pressure Injury/Ulcer located on the pelvis or lower extremity
3. Subject has a Pressure Injury/Ulcer present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
4. Subject has a Pressure Injury/Ulcer with a historical wound measurement showing less than 50% healing within 30 days prior to randomization
5. Subject has a Pressure Injury/Ulcer with screening wound measurement showing less than 25% healing within 14 days prior to randomization
6. Subject has a Pressure Injury/Ulcer Stage 2, 3, and 4 without infection or clinically visible exposed bone
7. Index ulcer is a minimum of 1cm2 and a maximum of 25cm2 at first treatment visit
8. Index ulcer has a maximum depth of 1cm at first screening visit
9. Pressure Injury/Ulcer is treated with offloading therapy while standing, sitting and lying down (if applicable to wound location) for 14 days prior to randomization
10. Adequate circulation of ulcer demonstrated by an ABI of \>0.7 and \<1.3, or TBI of \>0.6 within 30 days prior to randomization
11. Index ulcer is free of infection prior to randomization and during screening phase.
12. Index ulcer is free of necrotic debris prior to \[insert product/device\] application
13. Female subjects of childbearing potential having a negative pregnancy test prior to randomization
14. Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
15. Having a Mini Nutritional Assessment Score of 12 or higher indicated a normal nutritional status
16. Subject is able and willing to follow the protocol requirements
17. Subject had signed informed consent
18. If 2 or more ulcers are present, the ulcers must be separated by at least 1 cm

Exclusion Criteria:

1. Subject has a known life expectancy of \<1 year
2. Subject is unable to comply with protocol treatment
3. Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing
4. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
5. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
6. Known contraindications to tissue-engineered allograft
7. Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
8. Wound reduces in area by ≥25% after 14 days of SOC prior to randomization
9. Subject is pregnant or breastfeeding
10. Subject with history of immunosuppressant treatment (systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the ulcer surface for \>2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
12. Pressure Injury/Ulcer of Stage 4 grade with active osteomyelitis or exposed visible bone
13. Wound depth with visible exposed bone
14. HBOT within 14 days prior to randomization
15. Revascularization surgery on the index ulcer leg within 30 days of screening phase
16. Index ulcer suspicious of neoplasm in the opinion of the principal investigator

Primary outcomes:
measure: Complete Wound Closure
timeFrame: 1-16 weeks
Secondary outcomes:
measure: Percentage Wound Area Change
timeFrame: 1-16 weeks
measure: Time to Closure
timeFrame: 1-16 weeks
measure: Follow-Up Closure
timeFrame: 2 weeks
measure: Pain Assessment
timeFrame: Day 0, Day 14, Day 35, Day 56, Day 77, Day 98, Day 112
Other outcomes:
measure: Wound closure rate in comparison to initial area
timeFrame: Day 0 through Day 112
measure: Adverse Events and Serious Adverse Events
timeFrame: Day -14 through 126 days
Locations:
Study officials:
affiliation: SygNola Research Faculty
name: Abigail Chaffin, MD
role: STUDY_CHAIR
References: